Oral Ixazomib Maintenance Therapy in Multiple Myeloma.
Offidani M et al. Expert Rev Anticancer Ther. 2015 Nov 20. [Epub ahead of print].
Effective use of panobinostat in combination with other active agents in myeloma in a novel 5-drug combination: Case Report and Interesting Observations.
Rajan AM et al. Am J Hematol. 2015 Nov 17. doi: 10.1002/ajh.24244. [Epub ahead of print].
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E et al. Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13799. [Epub ahead of print].
First-in-man experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labelled pentixather in advanced stage multiple myeloma with extensive intra- and extramedullary disease.
Herrmann K et al. J Nucl Med. 2015 Nov 12. pii: jnumed.115.167361. [Epub ahead of print].
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Shah JJ et al. Clin Cancer Res. 2015 Nov 11. [Epub ahead of print].
Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma.
Hannon JL et al. Transfusion. 2015 Nov;55(11):2770. doi: 10.1111/trf.13267.